Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMA asks FDA to extend ephedrine comment period to evaluate effect on pseudoephedrine.

This article was originally published in The Tan Sheet

Executive Summary

NDMA SEEKS EXTENSION OF COMMENT PERIOD ON FDA's EPHEDRINE PROPOSAL to prohibit over-the-counter sale of the ingredient and its salts and analogs ("The Tan Sheet" July 31, p. 1). "There are no exigent circumstances to justify adherence" to the thirty-day comment period provided in FDA's July 27 proposal, the Nonprescription Drug Manufacturers Association said in an Aug. 4 letter to the agency. NDMA asked FDA to extend the comment period from Aug. 28 to Oct. 27.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel